Investigational drug · Phase 2
epacadostat
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Endometrial Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
61
Any phase or sponsor naming "epacadostat"
First trial start
2021
Jan 26, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "epacadostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Cancer
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "epacadostat" as an intervention, largest first.
- A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT02752074 · 706 participants · Start Jun 21, 2016 · Primary completion Jan 8, 2018
Drug: pembrolizumab + epacadostat; pembrolizumab + placebo · For: Melanoma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 129 sites in all
Incyte CorporationIncyte (INCY)
NCT02178722 · 444 participants · Start Jul 17, 2014 · Primary completion Nov 26, 2018
Drug: MK-3475; INCB024360 · For: Microsatellite-instability (MSI) High Colorectal Cancer (CRC); Endometrial Cancer; Head and Neck Cancer and 11 more
Sites: La Jolla, California; Los Angeles, California; Sacramento, California · 24 sites in all
Incyte CorporationIncyte (INCY)
NCT02327078 · 307 participants · Start Nov 26, 2014 · Primary completion Jun 16, 2020
Drug: Nivolumab; Epacadostat and 1 more · For: B-cell Malignancies; Colorectal Cancer (CRC); Head and Neck Cancer and 5 more
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 24 sites in all
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03322566 · 233 participants · Start Jan 9, 2018 · Primary completion Dec 13, 2018
Drug: Pembrolizumab; Epacadostat and 2 more · For: Lung Cancer
Sites: Daphne, Alabama; Goodyear, Arizona; Tucson, Arizona · 94 sites in all
Incyte CorporationIncyte (INCY)
NCT04463771 · 206 participants · Start Jan 26, 2021 · Primary completion May 29, 2026
Drug: retifanlimab; epacadostat and 3 more · For: Endometrial Cancer
Sites: Anchorage, Alaska; Phoenix, Arizona; Tucson, Arizona · 65 sites in all
Incyte CorporationIncyte (INCY)
NCT02318277 · 176 participants · Start Jan 5, 2015 · Primary completion Aug 28, 2019
Drug: MEDI4736; INCB024360 · For: Solid Tumors; Head and Neck Cancer; Lung Cancer and 1 more
Sites: San Francisco, California; Denver, Colorado; Miami, Florida · 13 sites in all
- Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03322540 · 154 participants · Start Dec 15, 2017 · Primary completion Jan 10, 2019
Drug: Pembrolizumab; Epacadostat and 1 more · For: Lung Cancer
Sites: Anaheim, California; Whittier, California; Fort Myers, Florida · 101 sites in all
Incyte CorporationIncyte (INCY)
NCT02559492 · 142 participants · Start Nov 2015 · Primary completion Sep 10, 2018
Drug: Itacitinib; Epacadostat and 2 more · For: Solid Tumors
Sites: Duarte, California; Denver, Colorado; New Haven, Connecticut · 11 sites in all
- Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03260894 · 129 participants · Start Dec 7, 2017 · Primary completion Aug 22, 2018
Drug: Pembrolizumab; Epacadostat and 2 more · For: Renal Cell Carcinoma (RCC)
Sites: Scottsdale, Arizona; Tucson, Arizona; Los Angeles, California · 140 sites in all
- Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)Pivotal-lookingCompleted
Incyte CorporationIncyte (INCY)
NCT03361865 · 93 participants · Start Dec 4, 2017 · Primary completion Aug 9, 2018
Drug: Pembrolizumab; Epacadostat and 1 more · For: UC (Urothelial Cancer)
Sites: Tucson, Arizona; Orange, California; New Haven, Connecticut · 143 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Porphyromonas gingivalis lipopolysaccharide induces osteoblast senescence and defective mineralization associated with indoleamine 2,3-dioxygenase 1-kynurenine-aryl hydrocarbon receptor signaling.
Han S, Zhang W, Zhang X, et al. · Life Sci 2026
- Integrated pan-cancer systems biology and structure-based simulation identifies Annona muricata-derived natural scaffolds as putative IDO1 modulators for cancer immunotherapy.
Hossain T, Ali MY, Riti FA, et al. · Comput Biol Chem 2026
- Targeting Kynurenine Synthesis Attenuated Cigarette Smoke-Induced COPD-Like Lung Injury Driven by TALDO1-Mediated Metabolic Reprogramming.
Wang W, Wu M, Yang Y, et al. · Adv Sci (Weinh) 2026
- Heterocyclic scaffolds targeting IDO1: progress in medicinal chemistry and clinical development.
Kumar A, Sharma V, Patel R, et al. · Future Med Chem 2026
- A Novel IDO1/NE Dual Inhibitor, IMM-H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression.
Zhou Y, Zhao X, Pan X, et al. · Adv Sci (Weinh) 2026
- Current applications and development of dual-target inhibitors of Ido1/TDO: From tumor immunology to neuropsychiatric disorders.
Guo W, Zhang JZ, Cui LY, et al. · Eur J Med Chem 2026
Also in development for Endometrial Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Incyte.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.